Infliximab in the treatment of amyloidosis secondary to Crohn's disease.
Authors: Cabezuelo JB,Egea JP,Ramos F,Torrella E,Muray S,Alcázar C,
Address: Hospital General Universitario Reina Sofía, Murcia, Spain. email@example.com
Publication: 2012 May 14;32(3):385-8. doi: 10.3265/Nefrologia.pre2012.Feb.11332.
secondary amyloidosis (AA) is a severe complication of progressed Crohn’s disease (CD) for which no effective treatment exists. We present the exceptional case of a 33 year-old male with moderate renal failure and proteinuria, who was simultaneously diagnosed with AA amyloid nephropathy and oligosymptomatic CD. He was treated with Infliximab at 5mg/kg/8 weeks for 4 years, azathioprine at 1-1.5mg/kg/day (first year) and renin-angiotensin-aldosterone system blockers, with no complications. Treatment caused a decrease in proteinuria, improved renal function, and improved inflammatory parameters over time. Inspired by this case, we performed a review of the medical literature and found that infliximab could be a useful tool in the early treatment of amyloidosis secondary to CD.
The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.